JP2024041896A5 - - Google Patents

Download PDF

Info

Publication number
JP2024041896A5
JP2024041896A5 JP2024002472A JP2024002472A JP2024041896A5 JP 2024041896 A5 JP2024041896 A5 JP 2024041896A5 JP 2024002472 A JP2024002472 A JP 2024002472A JP 2024002472 A JP2024002472 A JP 2024002472A JP 2024041896 A5 JP2024041896 A5 JP 2024041896A5
Authority
JP
Japan
Prior art keywords
substituent
present
composition
halogen
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024002472A
Other languages
English (en)
Other versions
JP2024041896A (ja
Filing date
Publication date
Priority claimed from JP2020526059A external-priority patent/JP7424637B2/ja
Application filed filed Critical
Publication of JP2024041896A publication Critical patent/JP2024041896A/ja
Publication of JP2024041896A5 publication Critical patent/JP2024041896A5/ja
Pending legal-status Critical Current

Links

Claims (6)

  1. ASH1LおよびE3リガーゼ複合体に結合可能であるタンパク質分解標的キメラ(PROTAC)化合物またはその塩を含む組成物であって、前記PROTAC化合物の構造は:

    を含み
    XはCHまたはNであり;
    ZはSまたはOであり;


    から選択され;
    、R 10 は、R 置換基中に存在する場合、それぞれ独立してH、CH 、F、CFH 、CF H、CF およびOHから選択され;
    は、前記R 置換基中に存在する場合、

    から選択され;
    11 は、前記R 置換基中に存在する場合、

    から選択され;
    は、独立してH、ハロゲン、CH 、OH、SH、NH 、CN、CF 、CCl 、-CH -CH 、-CH -OH、-CH NH 、CH Cl、CH Br、CH F、CHF 、CH CN、およびCH CF から選択され;
    Aは、

    であり;nは0~2であり;
    リガーゼリガンドはE3リガーゼ複合体に結合可能な分子であり、

    から選択され;
    リンカーはリガーゼリガンドとAとを結合可能な官能基である、組成物。
  2. ZがSであり、XがCHである、請求項1に記載の組成物。
  3. がHまたはハロゲンである、請求項1に記載の組成物。
  4. は下記

    から選択され;
    置換基中に存在する場合、R は、HおよびCH から選択され、R 10 はHであり;
    置換基中にR が存在する場合、R

    から選択され;
    置換基中にR 11 が存在する場合、R 11 は、

    から選択される;
    請求項1に記載の組成物。
  5. 前記XがCHであり;
    前記ZがSであり;
    前記R がHまたはハロゲンであり;


    から選択され;
    置換基中に存在する場合、R は、HおよびCH から選択され、R 10 がHであり、R はR 置換基中に存在する場合、

    から選択され;
    11 は、R 置換基中に存在する場合、

    から選択される、請求項1に記載の組成物。
  6. 前記XがCHであり;前記ZがSであり;
    前記R がHまたはハロゲンであり;


    から選択され;
    Aが

    であり、nが0であり;
    リガーゼリガンドがE3リガーゼ複合体に結合可能な分子であり、

    から選択され;
    リンカーが下記(i)および(ii)から選択される、請求項1に記載の組成物:
    (i)

    式中、nが2~6、Xが存在せず、mが0、kが2~4、YがO、Iが1である;
    (ii)

    式中、nが6~10、mが1、XはNHまたはOである。
JP2024002472A 2017-11-10 2024-01-11 Ash1l分解剤及びそれを用いた治療方法 Pending JP2024041896A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762584473P 2017-11-10 2017-11-10
US62/584,473 2017-11-10
JP2020526059A JP7424637B2 (ja) 2017-11-10 2018-11-09 Ash1l分解剤及びそれを用いた治療方法
PCT/US2018/060101 WO2019094772A1 (en) 2017-11-10 2018-11-09 Ash1l degraders and methods of treatment therewith

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020526059A Division JP7424637B2 (ja) 2017-11-10 2018-11-09 Ash1l分解剤及びそれを用いた治療方法

Publications (2)

Publication Number Publication Date
JP2024041896A JP2024041896A (ja) 2024-03-27
JP2024041896A5 true JP2024041896A5 (ja) 2024-04-10

Family

ID=66432988

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020526068A Pending JP2021502388A (ja) 2017-11-10 2018-11-09 Ash1l阻害剤及びそれを用いた治療方法
JP2020526059A Active JP7424637B2 (ja) 2017-11-10 2018-11-09 Ash1l分解剤及びそれを用いた治療方法
JP2024002472A Pending JP2024041896A (ja) 2017-11-10 2024-01-11 Ash1l分解剤及びそれを用いた治療方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2020526068A Pending JP2021502388A (ja) 2017-11-10 2018-11-09 Ash1l阻害剤及びそれを用いた治療方法
JP2020526059A Active JP7424637B2 (ja) 2017-11-10 2018-11-09 Ash1l分解剤及びそれを用いた治療方法

Country Status (6)

Country Link
US (5) US10632209B2 (ja)
EP (2) EP3706737A4 (ja)
JP (3) JP2021502388A (ja)
CN (2) CN111655257A (ja)
CA (2) CA3082086A1 (ja)
WO (2) WO2019094772A1 (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2910787T3 (es) 2016-05-12 2022-05-13 Univ Michigan Regents Inhibidores de ASH1L y métodos de tratamiento con los mismos
JP2021502388A (ja) * 2017-11-10 2021-01-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ash1l阻害剤及びそれを用いた治療方法
US11639354B2 (en) 2018-07-31 2023-05-02 Fimecs, Inc. Heterocyclic compound
CA3141413A1 (en) * 2019-06-12 2020-12-17 Xiaobao Yang Alk protein regulator and anti-tumor application thereof
KR102325607B1 (ko) * 2020-02-20 2021-11-12 한국과학기술원 Ash1l 히스톤 메틸화 효소 활성을 억제하는 벤조퓨란-피라졸 유도체 화합물을 포함하는 백혈병의 예방 또는 치료용 조성물
CN113004251B (zh) * 2021-03-05 2022-09-27 郑州大学第一附属医院 含2-硝基咪唑的喹唑啉类衍生物及其应用
CN115960104A (zh) * 2021-10-09 2023-04-14 嘉兴优博生物技术有限公司 靶向蛋白酶降解(ted)平台
WO2024080793A1 (en) * 2022-10-13 2024-04-18 Hanmi Pharm. Co., Ltd. Novel heterobicyclic compound for inhibiting yap-tead interaction and pharmaceutical composition comprising same

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5863A (en) 1848-10-17 Matthias p
US949A (en) 1838-09-27 Improvement in roller cotton-gins for ginning long-staple and other kinds of cotton
US5861A (en) 1848-10-17 Locking umbrella and parasol
US510A (en) 1837-12-07 soeel
US3993073A (en) 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4069307A (en) 1970-10-01 1978-01-17 Alza Corporation Drug-delivery device comprising certain polymeric materials for controlled release of drug
US3731683A (en) 1971-06-04 1973-05-08 Alza Corp Bandage for the controlled metering of topical drugs to the skin
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
BE795384A (fr) 1972-02-14 1973-08-13 Ici Ltd Pansements
US3921636A (en) 1973-01-15 1975-11-25 Alza Corp Novel drug delivery device
US3993072A (en) 1974-08-28 1976-11-23 Alza Corporation Microporous drug delivery device
US4151273A (en) 1974-10-31 1979-04-24 The Regents Of The University Of California Increasing the absorption rate of insoluble drugs
US3972995A (en) 1975-04-14 1976-08-03 American Home Products Corporation Dosage form
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4060084A (en) 1976-09-07 1977-11-29 Alza Corporation Method and therapeutic system for providing chemotherapy transdermally
US4201211A (en) 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
JPS5562012A (en) 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
US4230105A (en) 1978-11-13 1980-10-28 Merck & Co., Inc. Transdermal delivery of drugs
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4291015A (en) 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
US4476116A (en) 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
US5116817A (en) 1982-12-10 1992-05-26 Syntex (U.S.A.) Inc. LHRH preparations for intranasal administration
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
GB8522453D0 (en) 1985-09-11 1985-10-16 Lilly Industries Ltd Chewable capsules
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
IE900394L (en) 1989-02-08 1990-08-08 Abbott Lab Thiazole derivatives
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
US5633009A (en) 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
AU1537292A (en) 1991-04-16 1992-11-17 Nippon Shinyaku Co. Ltd. Method of manufacturing solid dispersion
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
US5281420A (en) 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
AU4198793A (en) 1992-07-24 1994-01-27 Takeda Chemical Industries Ltd. Microparticle preparation and production thereof
US5700485A (en) 1992-09-10 1997-12-23 Children's Medical Center Corporation Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5391452A (en) 1993-08-02 1995-02-21 Xerox Corporation Polyester toner and developer compositions
US5665378A (en) 1994-09-30 1997-09-09 Davis; Roosevelt Transdermal therapeutic formulation
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
ATE198326T1 (de) 1995-04-20 2001-01-15 Pfizer Arylsulfonamido-substituierte hydroxamsäure derivate als inhibitoren von mmp und tnf
SE9502244D0 (sv) 1995-06-20 1995-06-20 Bioglan Ab A composition and a process for the preparation thereof
ES2183905T3 (es) 1995-12-20 2003-04-01 Hoffmann La Roche Inhibidores de metaloproteasa de matriz.
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US6929801B2 (en) 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
US6923983B2 (en) 1996-02-19 2005-08-02 Acrux Dds Pty Ltd Transdermal delivery of hormones
JP3195756B2 (ja) 1996-07-04 2001-08-06 公子 吉水 潤滑補助体
EP0818442A3 (en) 1996-07-12 1998-12-30 Pfizer Inc. Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
IL127567A0 (en) 1996-07-18 1999-10-28 Pfizer Phosphinate based inhibitors of matrix metalloproteases
CA2264284A1 (en) 1996-08-23 1998-02-26 Ralph P. Robinson Arylsulfonylamino hydroxamic acid derivatives
ES2224277T3 (es) 1997-01-06 2005-03-01 Pfizer Inc. Derivados de sulfonas ciclicas.
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
TR199901849T2 (xx) 1997-02-03 2000-02-21 Pfizer Products Inc. Arils�lfonilamino hidroksamik asit t�revleri.
WO1998034915A1 (en) 1997-02-07 1998-08-13 Pfizer Inc. N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
IL131123A0 (en) 1997-02-11 2001-01-28 Pfizer Arylsulfonyl hydroxamic acid derivatives
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
NZ502309A (en) 1997-08-08 2002-02-01 Pfizer Prod Inc Aryloxyarylsulfonylamino hydroxamic acid derivatives and pharmaceutical use
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
JP4589529B2 (ja) 1997-12-24 2010-12-01 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Xa因子阻害剤としてのインドール誘導体
US5869090A (en) 1998-01-20 1999-02-09 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
US6946144B1 (en) 1998-07-08 2005-09-20 Oryxe Transdermal delivery system
PT1004578E (pt) 1998-11-05 2004-06-30 Pfizer Prod Inc Derivados hidroxamida do acido 5-oxo-pirrolidino-2-carboxilico
ATE400252T1 (de) 1999-02-10 2008-07-15 Pfizer Prod Inc Pharmazeutische feste dispersionen
US6511993B1 (en) 1999-06-03 2003-01-28 Kevin Neil Dack Metalloprotease inhibitors
EP1081137A1 (en) 1999-08-12 2001-03-07 Pfizer Products Inc. Selective inhibitors of aggrecanase in osteoarthritis treatment
US6960563B2 (en) 2001-08-31 2005-11-01 Morton Grove Pharmaceuticals, Inc. Spontaneous emulsions containing cyclosporine
JP4505566B2 (ja) * 2004-09-30 2010-07-21 愛知県 肺癌治療剤
US20080233101A1 (en) 2005-09-15 2008-09-25 The Regents Of The University Of California RNA-mediated epigenetic regulation of gene transcription
UA94600C2 (en) * 2006-01-24 2011-05-25 Эли Лилли Энд Компани Indole sulfonamide modulators of progesterone receptors
WO2007117465A2 (en) 2006-03-31 2007-10-18 Abbott Laboratories Indazole compounds
EP2041108B1 (en) 2006-07-18 2014-05-21 Antibe Holdings Inc. 4-hydroxythiobenzamide derivatives of drugs
CA2674895A1 (en) 2007-01-31 2008-08-07 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis, prognosis and treatment of acute myeloid leukemia (aml)
KR20090130065A (ko) 2007-04-13 2009-12-17 수퍼젠, 인크. 암 또는 과증식성 장애 치료에 유용한 Axl 키나제 억제제
WO2009015067A2 (en) * 2007-07-25 2009-01-29 Boehringer Ingelheim International Gmbh Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2009051956A2 (en) 2007-10-16 2009-04-23 E. I. Du Pont De Nemours And Company Pyrazole-substituted isoxazoline insecticides
RU2513636C2 (ru) * 2008-01-04 2014-04-20 Интелликайн ЭлЭлСи Некоторые химические структуры, композиции и способы
UA107938C2 (en) 2009-08-12 2015-03-10 Syngenta Participations Ag Heterocycles with microbicidal properties
EP2649099A4 (en) 2010-12-07 2016-10-19 Univ Yale HYDROPHOBIC MARKING OF SMALL MOLECULES OF FUSION PROTEINS AND INDUCED DEGRADATION THEREOF
AU2012220620A1 (en) * 2011-02-23 2013-10-03 Icahn School Of Medicine At Mount Sinai Inhibitors of bromodomains as modulators of gene expression
MX358660B (es) 2012-01-12 2018-08-30 Univ Yale Compuestos y metodos para degradacion mejorada de proteinas y otros polipeptidos elegidos como blanco mediante una ubiquitina ligasa e3.
SG11201503893RA (en) 2012-11-19 2015-06-29 Agency Science Tech & Res Method of treating cancer
KR20150129847A (ko) * 2013-03-15 2015-11-20 더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 융합 단백질 및 이들의 방법
SG11201506687RA (en) * 2013-03-15 2015-09-29 Plexxikon Inc Heterocyclic compounds and uses thereof
BR112016017045A2 (pt) * 2014-01-31 2017-08-08 Dana Farber Cancer Inst Inc Derivados de diazepano e usos dos mesmos
JP6778114B2 (ja) 2014-04-14 2020-10-28 アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. イミド系タンパク質分解モジュレーター及び関連する使用方法
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
JP2018527336A (ja) * 2015-08-10 2018-09-20 ファイザー・インク 3−インドール置換誘導体、医薬組成物、および使用方法
US20170158702A1 (en) * 2015-12-02 2017-06-08 Kyras Therapeutics, Inc. Multivalent ras binding compounds
WO2017176958A1 (en) * 2016-04-06 2017-10-12 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
SG11201808729WA (en) * 2016-04-12 2018-11-29 Univ Michigan Regents Bet protein degraders
AU2017254702B2 (en) 2016-04-22 2020-12-24 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 9 (CDK9) by conjugation of CDK9 inhibitors with E3 ligase ligand and methods of use
ES2910787T3 (es) * 2016-05-12 2022-05-13 Univ Michigan Regents Inhibidores de ASH1L y métodos de tratamiento con los mismos
JP2020505327A (ja) 2016-12-23 2020-02-20 アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. Egfrタンパク質分解標的化キメラ分子およびその関連する使用方法
JP2020504741A (ja) 2016-12-23 2020-02-13 アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. Raf(急速進行性線維肉腫)ポリペプチドの標的分解のための化合物および方法
EP3559006A4 (en) 2016-12-23 2021-03-03 Arvinas Operations, Inc. COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES
JP2021502388A (ja) 2017-11-10 2021-01-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ash1l阻害剤及びそれを用いた治療方法

Similar Documents

Publication Publication Date Title
JP2024041896A5 (ja)
JP2021169499A5 (ja)
JP2023166381A5 (ja)
RU2005126418A (ru) Синтез 4-амино-2-бутеноилхлоридов и их использование при получении 3-цианохинолинов
JP2022078315A5 (ja)
JP2004182741A5 (ja)
JP2005509735A5 (ja)
JPWO2019213318A5 (ja)
JP2007503388A5 (ja)
JP2008520662A5 (ja)
JP2009500415A5 (ja)
JP2008513432A5 (ja)
JP2005510563A5 (ja)
JP2011503096A5 (ja)
JP2002524449A5 (ja)
JP2006502283A5 (ja)
JP2005538089A5 (ja)
JP2007532575A5 (ja)
JP2005517643A5 (ja)
JP2021502386A5 (ja)
JP2023171659A5 (ja)
JP2005517008A5 (ja)
JP2006508979A5 (ja)
JPWO2019094772A5 (ja)
JP2004532276A5 (ja)